MIM
HCAT icon

MetLife Investment Management’s Health Catalyst HCAT Stock Holding History

MetLife Investment Management’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,979
Closed -$45.4K – 2803
2025
Q4 		$45.4K Sell
18,979
-19,053
-50% -$52.1K ﹤0.01% 2734
2025
Q3 		$108K Sell
38,032
-2,963
-7% -$10.1K ﹤0.01% 2618
2025
Q2 		$155K Buy
40,995
+21,352
+109% +$84K ﹤0.01% 2317
2025
Q1 		$89K Sell
19,643
-15,331
-44% -$81.1K ﹤0.01% 2579
2024
Q4 		$247K Buy
34,974
+507
+1% +$4.04K ﹤0.01% 2193
2024
Q3 		$281K Hold
34,467
– – ﹤0.01% 2104
2024
Q2 		$220K Buy
34,467
+7,014
+26% +$45K ﹤0.01% 2179
2024
Q1 		$207K Hold
27,453
– – ﹤0.01% 2188
2023
Q4 		$254K Hold
27,453
– – ﹤0.01% 2097
2023
Q3 		$278K Hold
27,453
– – ﹤0.01% 2003
2023
Q2 		$343K Hold
27,453
– – ﹤0.01% 1937
2023
Q1 		$320K Hold
27,453
– – ﹤0.01% 1914
2022
Q4 		$292K Hold
27,453
– – ﹤0.01% 2008
2022
Q3 		$266K Hold
27,453
– – ﹤0.01% 2108
2022
Q2 		$398K Hold
27,453
– – ﹤0.01% 1826
2022
Q1 		$717K Buy
27,453
+9,967
+57% +$283K ﹤0.01% 1545
2021
Q4 		$693K Hold
17,486
– – 0.01% 1311
2021
Q3 		$874K Buy
17,486
+1,339
+8% +$73K 0.01% 1191
2021
Q2 		$896K Buy
16,147
+1,503
+10% +$80.1K 0.01% 1230
2021
Q1 		$685K Hold
14,644
– – 0.01% 1343
2020
Q4 		$637K Hold
14,644
– – 0.01% 1361
2020
Q3 		$536K Hold
14,644
– – 0.01% 1333
2020
Q2 		$427K Buy
14,644
+6,010
+70% +$166K ﹤0.01% 1467
2020
Q1 		$226K Buy
8,634
+4,873
+130% +$149K ﹤0.01% 1633
2019
Q4 		$131K Sell
3,761
-3,228
-46% -$107K ﹤0.01% 2195
2019
Q3 		$221K Buy
+6,989
New +$275K ﹤0.01% 1888

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's HCAT Position: Q1 2026 in Review

MetLife Investment Management sold out of Health Catalyst (HCAT) in Q1 2026, closing a stake of 18,979 shares — an estimated $45.4K sold.

MetLife Investment Management first reported a position in HCAT in Q3 2019 and held it in 26 quarters. The position peaked at $896K in Q2 2021. 130 funds tracked by Wall St. Rank hold HCAT as of Q1 2026.

  • MetLife Investment Management reported no remaining Health Catalyst position as of Q1 2026 after selling out during the quarter.
  • MetLife Investment Management sold 18,979 Health Catalyst shares in Q1 2026, an estimated $45.4K.
  • MetLife Investment Management first reported a position in Health Catalyst in Q3 2019 and held it in 26 quarters.
  • MetLife Investment Management's Health Catalyst position peaked at $896K in Q2 2021.
  • 130 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.